Literature DB >> 21232657

Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma.

Katherine R Calvo1, Ola Landgren, Aldo M Roccaro, Irene M Ghobrial.   

Abstract

microRNAs (miRNAs) are increasingly recognized as significant players in oncogenesis and tumor biology through post-transcriptional gene regulation impacting broad pathways of proliferation, differentiation, apoptosis, metastasis, and cell survival. Recent studies have found abnormal expression of miRNAs in multiple myeloma (MM). Currently, the precise role of these miRNAs in the biology of MM remains to be elucidated, although they are predicted to be involved in plasma cell proliferation, survival, homing, or in MM cell interactions with the bone marrow microenvironment. Furthermore, a limited number of studies focusing on MM precursor disease (monoclonal gammopathy of undetermined significance [MGUS]) reveal significant differences in miRNA profiles between MGUS and normal plasma cells. Interestingly, several of the microRNAs differentially expressed in MGUS also show aberrant expression in MM, suggesting a role in early myelomagenesis. miRNA profiles can discriminate molecular subtypes of MM that are defined based on gene expression profiling (GEP) and cytogenetic abnormalities, demonstrating the potential diagnostic/prognostic utility of miRNA profiling for subclassification of MM. Given the relative stability of miRNA and ability to isolate miRNA from routine clinical specimens, miRNA analysis promises to facilitate personalized diagnostics and therapies, and to provide insights into the biology of early myelomagenesis. Copyright Â
© 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232657      PMCID: PMC4522916          DOI: 10.1053/j.seminhematol.2010.11.007

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  55 in total

1.  Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.

Authors:  Matthew W Jenner; Paola E Leone; Brian A Walker; Fiona M Ross; David C Johnson; David Gonzalez; Laura Chiecchio; Elisabet Dachs Cabanas; Gian Paolo Dagrada; Mathew Nightingale; Rebecca K M Protheroe; David Stockley; Monica Else; Nicholas J Dickens; Nicholas C P Cross; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

2.  Intronic microRNA: discovery and biological implications.

Authors:  Sung-Chou Li; Petrus Tang; Wen-Chang Lin
Journal:  DNA Cell Biol       Date:  2007-04       Impact factor: 3.311

3.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

4.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  MicroRNAs modulate hematopoietic lineage differentiation.

Authors:  Chang-Zheng Chen; Ling Li; Harvey F Lodish; David P Bartel
Journal:  Science       Date:  2003-12-04       Impact factor: 47.728

6.  Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Laura Z Rassenti; Angelo Veronese; Cristian Taccioli; Stefan Costinean; Baltazar D Aguda; Stefano Volinia; Manuela Ferracin; Jeff Palatini; Veronica Balatti; Hansjuerg Alder; Massimo Negrini; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

Review 7.  MiRNAs and cancer.

Authors:  Rosa Visone; Carlo M Croce
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

8.  Functional integration of microRNAs into oncogenic and tumor suppressor pathways.

Authors:  Craig D Lotterman; Oliver A Kent; Joshua T Mendell
Journal:  Cell Cycle       Date:  2008-08-17       Impact factor: 4.534

9.  Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma.

Authors:  Sophie L Corthals; Mojca Jongen-Lavrencic; Yvonne de Knegt; Justine K Peeters; H Berna Beverloo; Henk M Lokhorst; Pieter Sonneveld
Journal:  Leuk Res       Date:  2009-12-23       Impact factor: 3.156

10.  An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

Authors:  Domenica Ronchetti; Marta Lionetti; Laura Mosca; Luca Agnelli; Adrian Andronache; Sonia Fabris; Giorgio Lambertenghi Deliliers; Antonino Neri
Journal:  BMC Med Genomics       Date:  2008-08-13       Impact factor: 3.063

View more
  8 in total

Review 1.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.

Authors:  Weixin Wang; Meghan Corrigan-Cummins; Emily A Barber; Layla M Saleh; Adriana Zingone; Azam Ghafoor; Rene Costello; Yong Zhang; Roger J Kurlander; Neha Korde; Aldo M Roccaro; Irene M Ghobrial; Ola Landgren; Katherine R Calvo
Journal:  J Mol Diagn       Date:  2015-09-30       Impact factor: 5.568

Review 3.  The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis.

Authors:  Leonidas Benetatos; Eleftheria Hatzimichael; Eric Londin; George Vartholomatos; Phillipe Loher; Isidore Rigoutsos; Evangelos Briasoulis
Journal:  Cell Mol Life Sci       Date:  2012-07-24       Impact factor: 9.261

Review 4.  MicroRNA theragnostics for the clinical management of multiple myeloma.

Authors:  N Ahmad; S Haider; S Jagannathan; E Anaissie; J J Driscoll
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

5.  Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance.

Authors:  Weixin Wang; Youn K Shim; Joel E Michalek; Emily Barber; Layla M Saleh; Byeong Yeob Choi; Chen-Pin Wang; Norma Ketchum; Rene Costello; Gerald E Marti; Robert F Vogt; Ola Landgren; Katherine R Calvo
Journal:  J Toxicol Environ Health A       Date:  2020-04-14

Review 6.  Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.

Authors:  Ola Landgren; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2013-11-22       Impact factor: 12.531

7.  Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome.

Authors:  Tanjung A Sumekar; Aneel A Ashrani; Tri I Winarni; Randi J Hagerman
Journal:  Case Rep Genet       Date:  2011-12-01

Review 8.  Circulating microRNAs and Their Role in Multiple Myeloma.

Authors:  Cinzia Federico; Antonio Sacco; Angelo Belotti; Rossella Ribolla; Valeria Cancelli; Arianna Giacomini; Roberto Ronca; Marco Chiarini; Luisa Imberti; Mirella Marini; Giuseppe Rossi; Marco Presta; Bruno Paiva; Aldo M Roccaro
Journal:  Noncoding RNA       Date:  2019-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.